Das, Satya

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology

Cancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug Reactions

Cited by 2,674

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

Das, S., & Johnson, D. B. (2019) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 1,145

177 Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors

Das, S., Al-Toubah, T., El-Haddad, G., & Strosberg, J. (2019) · Expert Review of Gastroenterology & Hepatology

Neuroendocrine Tumor Research AdvancesRadiopharmaceutical Chemistry and Applications

Cited by 135

Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy

Das, S., Ciombor, K. K., Haraldsdottir, S., Pumpalova, Y., Sahin, I. H., Pineda, G., Shyr, Y., Lin, E. P., Hsu, C.-Y., Chu, S.-K., et al. (2020) · The Oncologist

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 41

Immune checkpoint inhibitors (ICIs) in gastrointestinal (GI) cancer: Immune-related adverse events (IRAEs) and efficacy.

Das, S., Ciombor, K. K., Haraldsdottir, S., Pumpalova, Y. S., Sahin, I. H., Shyr, Y., Chu, S.-K., Lin, E. P.-Y., Hsu, C.-Y., Goff, L. W., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 15